Attrition

Blog
September 10, 2018

Over the last three decades, a range of biomedical and behavioral approaches have dramatically reduced HIV incidence throughout the world and improved the quality and availability of life-saving treatment for those living with HIV.

News
August 23, 2018

This year, 2018, will be the year that a really significant number of people in Africa started HIV pre-exposure prophylaxis (PrEP), the 22nd International AIDS Conference (AIDS 2018) in Amsterdam heard last week.

Resource
August 23, 2018

Background: The recent scale-up of prevention of mother-to-child transmission of HIV (PMTCT) services has rapidly accelerated antiretroviral therapy (ART) uptake among pregnant and postpartum women in sub-Saharan Africa.

Resource
March 29, 2018

The Sustainable Development Goals (SDGs) present a groundbreaking global development agenda to protect the most vulnerable.

Resource
March 29, 2018

Injectable contraceptives are popular in sub-Saharan Africa but have high discontinuation rates due partly to the need for provider-administered re-injection.

Resource
February 8, 2018

Although several studies have explored factors associated with loss to follow-up (LTFU) from HIV care, there remains a gap in understanding how these factors vary by setting, volume of patient and patients’ demographic and clinical characteristics.

Resource
February 5, 2018

Communities in South Africa’s informal settlements consist of ad-hoc and improvised housing whose residents seek opportunities for employment in the surrounding area.

Resource
February 1, 2018

Retention of patients in HIV care is crucial to ensure timely treatment initiation, viral suppression, and to avert AIDS-related deaths. We did a randomised trial to determine whether a text-messaging intervention improved retention during the first year of HIV care.

Resource
January 30, 2018

In 2013, Uganda updated its prevention of maternal-to-child transmission of HIV program to Option B+, which requires that all HIV-infected pregnant and breastfeeding women be started on lifelong antiretroviral therapy (ART) regardless of CD4 count.